NCT06104917

Effect of Maolactin on Gastrointestinal Tract (GIT) Health

Effect of MaolactinTM Supplement on Gastrointestinal Tract (GIT) Health in Adult Subjects: a Double-blind Randomized Placebo-controlled Study

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 91 (actual)
• Sponsor: RDC Clinical Pty Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind, placebo-controlled, 3 arm parallel group study of 12 weeks duration, with a 4-week run-in period as the control phase and an 8-week intervention period, to investigate the effectiveness of the treatment on upper GI disturbance.

Conditions

• Gastrointestinal Dysfunction

Interventions

Type	Name	Description
DRUG	High Dose Maolactin	Once daily dose of 2 capsules (2 capsules containing 250mg active proteins per capsule; equivalent to 500mg active proteins per day)
DRUG	Low Dose Maolactin	Once daily dose of 2 capsules (1 capsule containing 250mg active proteins per capsule and 1 capsule containing maltodextrin only; equivalent to 250mg active proteins per day)
DRUG	Maltodextrin	Once daily dose of 2 capsules

Timeline

• Start date: 2024-02-21
• Primary completion: 2025-07-23
• Completion: 2025-07-23
• First posted: 2023-10-27
• Last updated: 2025-08-26

Locations

1 site across 1 country: Australia